Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:AVDL NASDAQ:DRUG NASDAQ:JANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$11.27-3.0%$12.06$6.55▼$13.54$1.48B1.251.86 million shs1.34 million shsAVDLAvadel Pharmaceuticals$14.00-1.4%$14.57$6.38▼$16.66$1.36B1.461.32 million shs875,720 shsDRUGBright Minds Biosciences$63.29+3.1%$46.23$1.04▼$79.02$445.81M-6.1795,556 shs112,073 shsJANXJanux Therapeutics$26.51+2.6%$23.85$21.73▼$71.71$1.59B2.82853,375 shs1.01 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals-3.01%-0.70%-7.77%+28.07%+66.96%AVDLAvadel Pharmaceuticals-1.41%-6.73%-11.45%+45.68%+12.54%DRUGBright Minds Biosciences+3.06%+18.83%+50.08%+155.10%+5,902.47%JANXJanux Therapeutics+2.55%+10.46%+9.05%+5.41%-42.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$11.27-3.0%$12.06$6.55▼$13.54$1.48B1.251.86 million shs1.34 million shsAVDLAvadel Pharmaceuticals$14.00-1.4%$14.57$6.38▼$16.66$1.36B1.461.32 million shs875,720 shsDRUGBright Minds Biosciences$63.29+3.1%$46.23$1.04▼$79.02$445.81M-6.1795,556 shs112,073 shsJANXJanux Therapeutics$26.51+2.6%$23.85$21.73▼$71.71$1.59B2.82853,375 shs1.01 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals-3.01%-0.70%-7.77%+28.07%+66.96%AVDLAvadel Pharmaceuticals-1.41%-6.73%-11.45%+45.68%+12.54%DRUGBright Minds Biosciences+3.06%+18.83%+50.08%+155.10%+5,902.47%JANXJanux Therapeutics+2.55%+10.46%+9.05%+5.41%-42.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.67Moderate Buy$13.0015.35% UpsideAVDLAvadel Pharmaceuticals 2.70Moderate Buy$20.8648.98% UpsideDRUGBright Minds Biosciences 3.11Buy$81.0027.98% UpsideJANXJanux Therapeutics 2.94Moderate Buy$78.31195.39% UpsideCurrent Analyst Ratings BreakdownLatest DRUG, AUPH, AVDL, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AUPHAurinia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025AVDLAvadel PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025JANXJanux TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/27/2025AUPHAurinia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025AVDLAvadel PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025JANXJanux TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/17/2025JANXJanux TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$47.009/16/2025JANXJanux TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$47.009/15/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.009/10/2025JANXJanux TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$100.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M6.31$0.31 per share36.54$2.68 per share4.21AVDLAvadel Pharmaceuticals$169.12M8.04N/AN/A$0.77 per share18.18DRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AJANXJanux Therapeutics$10.59M150.42N/AN/A$19.49 per share1.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.4326.2120.13N/A23.31%20.06%13.81%11/6/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A233.33N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.93N/AN/AN/AN/A-20.96%-20.66%12/29/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)Latest DRUG, AUPH, AVDL, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025AUPHAurinia Pharmaceuticals$0.17N/AN/AN/A$67.70 millionN/A11/5/2025Q3 2025JANXJanux Therapeutics-$0.60N/AN/AN/A$3.07 millionN/A8/14/2025Q3 2025DRUGBright Minds Biosciences-$0.59-$0.53+$0.06-$0.53N/AN/A8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A7/31/2025Q2 2025AUPHAurinia Pharmaceuticals$0.17$0.16-$0.01$0.16$64.27 million$70.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.185.234.63AVDLAvadel PharmaceuticalsN/A2.792.38DRUGBright Minds BiosciencesN/A86.6486.64JANXJanux TherapeuticsN/A47.0347.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%AVDLAvadel Pharmaceuticals69.19%DRUGBright Minds Biosciences40.52%JANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%AVDLAvadel Pharmaceuticals5.20%DRUGBright Minds Biosciences42.66%JANXJanux Therapeutics8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300131.63 million115.57 millionOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableJANXJanux Therapeutics3060.09 million55.23 millionOptionableDRUG, AUPH, AVDL, and JANX HeadlinesRecent News About These CompaniesWhy Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer TherapiesOctober 10 at 9:51 PM | finance.yahoo.comJanux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?October 10 at 11:10 AM | zacks.comWeiss Ratings Reaffirms Sell (D-) Rating for Janux Therapeutics (NASDAQ:JANX)October 9 at 5:07 AM | marketbeat.comAnalysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $78.31October 4, 2025 | americanbankingnews.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by AnalystsSeptember 29, 2025 | marketbeat.comVoya Investment Management LLC Has $594,000 Stock Position in Janux Therapeutics, Inc. $JANXSeptember 26, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Sets New 1-Year Low - Time to Sell?September 25, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Raised to Strong-Buy at BarclaysSeptember 19, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Up - Here's WhySeptember 18, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Now Covered by BarclaysSeptember 18, 2025 | marketbeat.comBarclays Initiates Coverage of Janux Therapeutics (JANX) with Overweight RecommendationSeptember 17, 2025 | msn.comJanux Therapeutics initiated with an Overweight at BarclaysSeptember 16, 2025 | msn.comGoldman Sachs Group Inc. Has $7.73 Million Stock Holdings in Janux Therapeutics, Inc. $JANXSeptember 16, 2025 | marketbeat.comTruist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PTSeptember 15, 2025 | msn.comJanux Therapeutics (NASDAQ:JANX) Now Covered by Truist FinancialSeptember 12, 2025 | marketbeat.comStifel Nicolaus Reaffirms Buy Rating for Janux Therapeutics (NASDAQ:JANX)September 12, 2025 | marketbeat.comWoodline Partners LP Sells 395,092 Shares of Janux Therapeutics, Inc. $JANXSeptember 12, 2025 | marketbeat.comJanux Therapeutics initiated with a Buy at TruistSeptember 11, 2025 | msn.comTruist Securities Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationSeptember 11, 2025 | msn.comJanux Therapeutics resumed with a Buy at StifelSeptember 10, 2025 | msn.comJanux is a new Buy at Truist ahead of catalyst rich H2September 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Eli Lilly’s Oral GLP-1 Breakthrough Could Change EverythingBy Chris Markoch | September 18, 2025Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma GiantsBy Gabriel Osorio-Mazilli | October 6, 2025TrumpRx Brings Pfizer Into the Green—Is It a Buy?By Jordan Chussler | October 7, 2025DRUG, AUPH, AVDL, and JANX Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$11.27 -0.35 (-3.01%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$11.32 +0.05 (+0.44%) As of 10/10/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Avadel Pharmaceuticals NASDAQ:AVDL$14.00 -0.20 (-1.41%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$13.89 -0.11 (-0.79%) As of 10/10/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Bright Minds Biosciences NASDAQ:DRUG$63.29 +1.88 (+3.06%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$61.00 -2.29 (-3.62%) As of 10/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Janux Therapeutics NASDAQ:JANX$26.51 +0.66 (+2.55%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$25.50 -1.01 (-3.79%) As of 10/10/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
